[{"notes_id":"1_772","category":"6","subcategory":"2","title":"Rheumatoid arthritis: management","body":"The management of rheumatoid arthritis (RA) has been revolutionised by the introduction of disease-modifying therapies in the past decade. <br \/><br \/>Patients with evidence of joint inflammation should start a combination of disease-modifying drugs (DMARD) as soon as possible. Other important treatment options include analgesia, physiotherapy and surgery.<br \/><br \/>Initial therapy<br \/><ul><li>NICE recommend <span class=\"concept\" data-cid=\"12111\">DMARD <b>monotherapy<\/b> +\/- a short-course of bridging prednisolone<\/span>. In the past dual DMARD therapy was advocated as the initial step<\/li><li>choices for initial DMARD monotherapy:<ul><li><b>methotrexate<\/b> is the most widely used DMARD. Monitoring of FBC & LFTs is essential due to the risk of myelosuppression and liver cirrhosis. Other important side-effects include pneumonitis<\/li><li>sulfasalazine<\/li><li>leflunomide<\/li><li>hydroxychloroquine: should only be considered for initial therapy if mild or palindromic disease<\/li><\/ul><\/li><\/ul><br \/>Monitoring response to treatment<br \/><ul><li>NICE recommends using a combination of CRP and disease activity (using a composite score such as <span class=\"concept\" data-cid=\"5830\">DAS28<\/span>) to assess response to treatment<\/li><\/ul><br \/>Flares<br \/><ul><li><span class=\"concept\" data-cid=\"2657\">flares of RA are often managed with corticosteroids - oral or intramuscular<\/span><\/li><\/ul><br \/>TNF-inhibitors<br \/><ul><li>the current indication for a TNF-inhibitor is an inadequate response to at least two DMARDs including methotrexate<\/li><li>etanercept: recombinant human protein, acts as a decoy receptor for TNF-&alpha;, subcutaneous administration, can cause demyelination, risks include <span class=\"concept\" data-cid=\"855\">reactivation of tuberculosis<\/span><\/li><li>infliximab: monoclonal antibody, binds to TNF-&alpha; and prevents it from binding with TNF receptors, intravenous administration, risks include reactivation of tuberculosis<\/li><li>adalimumab: monoclonal antibody, subcutaneous administration<\/li><\/ul><br \/>Rituximab<br \/><ul><li>anti-CD20 monoclonal antibody, results in B-cell depletion<\/li><li>two 1g intravenous infusions are given two weeks apart<\/li><li>infusion reactions are common<\/li><\/ul><br \/>Abatacept<br \/><ul><li>fusion protein that modulates a key signal required for activation of T lymphocytes<\/li><li>leads to decreased T-cell proliferation and cytokine production<\/li><li>given as an infusion<\/li><li>not currently recommend by NICE<\/li><\/ul>","notes_hash":"c1ca4c94f51c3cfd76adf22ce442dfb3","knowledge_graph_node_id_link":1093,"links":"<table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_844\" data-linkid=\"844\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_844\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">6<\/span><button type=\"button\" style=\"\" id=\"link_dislike_844\" data-linkid=\"844\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_844\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">17<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng100\">2018 Rheumatoid arthritis guidelines<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/rhwe0fb2Um4\" data-description=\"Rheumatoid arthritis\" data-upvotes=\"8\" data-downvotes=\"0\" data-media=\"456\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/rhwe0fb2Um4\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/rhwe0fb2Um4\" data-description=\"Rheumatoid arthritis\" data-upvotes=\"8\" data-downvotes=\"0\" data-media=\"456\">Rheumatoid arthritis<\/a><\/td><\/tr><tr><td><span ><small>Osmosis - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_797\" data-mediaid=\"797\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_797\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">8<\/span><button type=\"button\" style=\"\" id=\"media_dislike_797\" data-mediaid=\"797\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_797\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">0<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"855":{"concept_text":"<b>T<\/b>NF-#alpha# inhibitors may reactivate <b>T<\/b>B","concept_percentile":"80"},"2657":{"concept_text":"Intramuscular steroids such as methylprednisolone are used to manage the acute flares of rheumatoid arthritis\r\n","concept_percentile":"98"},"12111":{"concept_text":"Rheumatoid arthritis: initial management is conventional DMARD monotherapy (usually methotrexate), often with short-term bridging corticosteroid","concept_percentile":"88"}},"category_name":"Musculoskeletal","subcategory_name":"Rheumatology","comment_count":9},"",[]]